Crucially, although MEK inhibition has been demonstrated to block naive CD8+ T cell priming in a colon cancer model, the number of CD8+ effector T cells within the tumor were increased, and could potentiate immune checkpoint therapy (Ebert et al., 2016). Here, CD8A is linked to colonic neoplasm.